Literature DB >> 8513033

Single-photon emission computed tomography with 99mTc-exametazime in unmedicated schizophrenic patients.

K P Ebmeier1, D H Blackwood, C Murray, V Souza, M Walker, N Dougall, A P Moffoot, R E O'Carroll, G M Goodwin.   

Abstract

We examined 20 actively psychotic unmedicated schizophrenic patients and 20 matched control subjects by using single-photon emission, computed tomography (SPECT) with 99mtechnetium-exametazime. Patients showed a hyperfrontal pattern of tracer uptake with significant relative increases in superior prefrontal cortex. This abnormality was less pronounced in patients with higher symptom scores for psychomotor poverty. In addition, patients showed associations between certain schizophrenic syndrome scores, such as psychomotor poverty, disorganization, and reality distortion, and tracer uptake to a number of cortical and subcortical brain regions. This syndrome-related pattern of tracer uptake was, at least in part, consistent with similar associations previously reported in chronically medicated schizophrenic patients. SPECT therefore provides a readily available method to examine the relationship between symptom pattern and regional brain metabolism in psychotic patients. Any observed patterns of association will depend on the current mental and medication status of the patients examined.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513033     DOI: 10.1016/0006-3223(93)90002-u

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  17 in total

1.  Functional neuroimaging in mental disorders.

Authors:  Philip K McGuire; Kazunori Matsumoto
Journal:  World Psychiatry       Date:  2004-02       Impact factor: 49.548

2.  Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia.

Authors:  Carol J Lane; Elton T C Ngan; Lakshmi N Yatham; Tom J Ruth; Peter F Liddle
Journal:  J Psychiatry Neurosci       Date:  2004-01       Impact factor: 6.186

3.  Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study.

Authors:  M Soyka; W Koch; H J Möller; T Rüther; K Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04-18       Impact factor: 5.270

4.  Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naïve schizophrenic patients: correlations with symptom change.

Authors:  E T C Ngan; C J Lane; T J Ruth; P F Liddle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

Review 5.  Neurobiological background of negative symptoms.

Authors:  Silvana Galderisi; Eleonora Merlotti; Armida Mucci
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03-24       Impact factor: 5.270

Review 6.  Neuroimaging biomarkers for early drug development in schizophrenia.

Authors:  Jason R Tregellas
Journal:  Biol Psychiatry       Date:  2013-10-04       Impact factor: 13.382

7.  Inner connections within domain of dementia praecox: role of supervisory mental processes in schizophrenia.

Authors:  P F Liddle
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

8.  Brain single-photon emission tomography with technetium-99m hexamethylpropylene amine oxime in adolescents with initial-stage schizophrenia.

Authors:  J F Batista; M C Galiano; L A Torres; M C Hernández; F Sosa; A Perera; M Pérez
Journal:  Eur J Nucl Med       Date:  1995-11

9.  Hypofrontality revisited: a high resolution single photon emission computed tomography study in schizophrenia.

Authors:  K P Ebmeier; S M Lawrie; D H Blackwood; E C Johnstone; G M Goodwin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-04       Impact factor: 10.154

10.  Effects of a ketogenic diet on auditory gating in DBA/2 mice: A proof-of-concept study.

Authors:  Jason R Tregellas; Jason Smucny; Kristina T Legget; Karen E Stevens
Journal:  Schizophr Res       Date:  2015-10-09       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.